Clinical trials: Hematologic Neoplasms
- Condition Hematologic Neoplasms
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Acute Myeloid Leukemia
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT01853228
- Testing
- Phase1 and Phase 2: decitabine, Phase 1: cytarabine, Phase 2: cytarabine
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Non-hodgkin Lymphoma
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05206357
- Testing
- Epcoritamab
- Where
- 41 sites in United States, Australia and 12 more
- Volunteers
- 17 people
- Sponsor
- Genmab
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
This study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
- Trial name
- NCT00089596
- Testing
- Expansion of umbilical cord stem cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- ViaCell
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
- Trial name
- THRIVE (NCT03699475)
- Testing
- rivogenlecleucel, rimiducid, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Leukemia
Aminopterin in Treating Patients With Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory…
- Trial name
- NCT00003305
- Testing
- aminopterin, leucovorin calcium
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Lymphoblastic Leukemia (ALL)
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of Phase 1b of this study is to: Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia…
- Trial name
- NCT02303821
- Testing
- Carfilzomib, Dexamethasone, Mitoxantrone
- Where
- 122 sites in United States, Argentina and 31 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Relapsed/Refractory Acute Leukemia
Expanded Access Program for Revumenib
This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no…
- Trial name
- NCT05918913
- Testing
- Revumenib
- Where
- 35 sites in United States
- Sponsor
- Syndax Pharmaceuticals
Acute Myelocytic Leukemia
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia.
- Trial name
- NCT03796390
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
B-Cell Pediatric ALL
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.
- Trial name
- NCT02227108
- Testing
- Moxetumomab Pasudotox
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 37 people
- Sponsor
- MedImmune LLC
Acute Lymphocytic Leukemia
Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia
This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Senl_1904A and Senl_1904B) targeting cluster of differentiation antigen 19…
- Trial name
- NCT03840317
- Testing
- Autologous CD19-targeting CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Advanced MDS, Acute Myeloid Leukemia
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
This is a 2-phase study during which patients with select myeloid leukemias or advanced myelodysplastic syndrome (MDS), who have failed, refused or are not eligible for standard treatment, will receive investigational study drug…
- Trial name
- NCT00637052
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Infection, Febrile Neutropenia
Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients
The aim of the study is to evaluate the efficacy and safety of Teicoplanin versus Vancomycin as part of the initial antibiotic regimen in the therapy of patients with fever and neutropenia .
- Trial name
- NCT00454272
- Testing
- Teicoplanin, Vancomycin
- Where
- Turkey (Türkiye)
- Volunteers
- 197 people
- Sponsor
- Sanofi
Acute Lymphoblastic Leukemia
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel).
- Trial name
- KareALL (NCT07039383)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Sarcoma, Neutropenia
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced.
- Trial name
- NCT00035620
- Testing
- pegfilgrastim, filgrastim
- Volunteers
- 44 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia
Special Drug Use-results Surveillance of Scemblix Tablets
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
- Trial name
- NCT05421091
- Testing
- Asciminib
- Where
- 278 sites in Japan
- Volunteers
- 550 people
- Sponsor
- Novartis Pharmaceuticals